Background. Klotho is a transmembrane protein that acts as a cofactor for fibroblast growth factor 23 (FGF23). Klotho also exists as a soluble circulating protein, but its role in secondary hyperparathyroidism (SHPT) is largely unknown. Methods. We measured serum soluble Klotho levels in 51 haemodialysis patients, who participated and completed a 52-week, multicentre, open-label single-arm trial that examined the effectiveness of cinacalcet for treating SHPT. Results. After 12 weeks of cinacalcet treatment, serum soluble Klotho decreased significantly (P ¼ 0.03) but only marginally from 398 pg/mL [interquartile range (IQR), 268-588 pg/mL] to 378 pg/mL (IQR, 266-568 pg/mL) and returned to baseline levels. There were no significant associations between the changes in soluble Klotho levels and changes in any other parameters of mineral metabolism, including serum calcium, phosphorus, intact parathyroid hormone and FGF23. Conclusion. Despite significant alterations in mineral and bone metabolism during treatment with cinacalcet, this resulted in only small and transient reductions in serum levels of soluble Klotho.
Introduction
Klotho, originally identified as an anti-ageing protein [1] , is a single-pass transmembrane protein that acts as a co-receptor for fibroblast growth factor 23 (FGF23) [2, 3] . Klotho is also cleaved and released into the circulation and functions as a humoral factor. Recent experimental studies suggest that this soluble form of Klotho plays a role in the regulation of mineral homeostasis. Secreted Klotho enhances calcium reabsorption in the distal nephron by activating the transient receptor potential v-5 [4, 5] and also functions as a phosphaturic substance via its enzymatic action on renal sodiumdependent phosphate transporter 2a [6] . However, the role and regulation of soluble Klotho in patients with end-stage kidney disease (ESKD) is largely unknown. In this study, we examined the effects of cinacalcet hydrochloride, an allosteric modulator of the calcium-sensing receptor (CaSR) [7À9], on serum soluble Klotho levels in haemodialysis patients with secondary hyperparathyroidism (SHPT).
Materials and methods

Study design
This was a post hoc analysis of a 52-week, multicentre, open-label singlearm trial that examined the effectiveness of cinacalcet in maintenance haemodialysis patients with SHPT. The study procedures have been described elsewhere [9] . The study was conducted in accordance with the principles of the Declaration of Helsinki. The study protocol was approved by the institutional review board of Kobe University School of Medicine, which waived the need for additional written informed consent for the post hoc analysis.
Measurements
Serum samples were collected prospectively at baseline and after 12, 24 and 52 weeks. Serum soluble Klotho levels were determined using a sandwich ELISA kit according to the manufacturer's protocol (ImmunoBiological Laboratories, Co., Ltd, Gunma, Japan). This assay detects circulating soluble Klotho by using two monoclonal antibodies that specifically recognize the extracellular domain of Klotho. The intra-and interassay coefficients of variation were <10% [10] . Serum full-length FGF23 levels were determined using a sandwich ELISA kit (Kainos Laboratories, Tokyo, Japan). Serum intact parathyroid hormone (PTH) levels were determined using an electrochemiluminescence immunoassay (Elecsys PTH; Roche Diagnostics, Mannheim, Germany). Serum calcium levels were corrected for albumin concentration using Payne's formula [11] .
Statistical analysis
Data are reported as mean AE SD or median [interquartile range (IQR)] as appropriate. Associations between parameters were examined by Spearman's rank test. Changes from baseline in biochemical parameters were analysed using repeated measures analysis of variance (ANOVA) followed by Bonferroni post hoc test. As serum intact PTH, FGF23 and soluble Klotho levels were not normally distributed, the values were log transformed for the ANOVA. P <0.05 was considered statistically significant. All analyses were performed using IBM SPSS Statistics 20 (IBM SPSS, Tokyo, Japan).
Results
Study population and baseline results
Of the 81 patients enrolled in the original trial, 51 completed the 52-week trial and had serum samples available for analysis (Table 1) . At baseline, median serum soluble Klotho was 398 pg/mL (IQR, 268-588 pg/mL). The serum levels of soluble Klotho were associated significantly with serum calcium levels (r ¼ 0.29, P ¼ 0.04), but not with age (r ¼ À0.21, P ¼ 0.1), duration of dialysis (r ¼ 0.08, P ¼ 0.6), phosphorus (r ¼ À0.23, P ¼ 0.1), intact PTH levels (r ¼ 0.02, P ¼ 0.9) or FGF23 levels (r ¼ À0.05, P ¼ 0.7).
Effect of cinacalcet on serum soluble Klotho
Treatment with cinacalcet resulted in significant and sustained reductions in serum calcium, phosphorus, intact PTH and FGF23 levels ( Table 2 ). In contrast, soluble Klotho levels showed a small but significant decrease after 12 weeks of treatment [378 pg/mL (IQR, 266-568 pg/mL), P ¼ 0.03] and then returned to baseline values (Figure 1 ). There were no significant associations between the changes in soluble Klotho levels from baseline to Week 12 and changes in any other parameters of mineral metabolism, including serum calcium (r ¼ 0.11, P ¼ 0.9), phosphorus (r ¼ 0.16, P ¼ 0.3), intact PTH (r ¼ À0.87, P ¼ 0.5) and FGF23 (r ¼ 0.22, P ¼ 0.1).
Discussion
Treatment with cinacalcet has marked effects on biochemical parameters of SHPT [7] [8] [9] and also lowers serum FGF23 levels [12, 13] . However, in this study, cinacalcet treatment of SHPT resulted in only small and transient reductions in serum levels of soluble Klotho.
In patients with ESKD, Klotho expression is decreased significantly in both the kidney [14] and hyperplastic parathyroid glands [15, 16] . A recent experimental study also showed very low renal, plasma and urinary levels of Klotho in mice with chronic kidney disease (CKD) and proposed that CKD is a state of Klotho deficiency [17] . In line with these observations, we found that serum levels of soluble Klotho were modestly reduced in patients on haemodialysis compared to values reported in healthy adults [10] . Further studies are, however, needed to determine the source and metabolism of circulating soluble Klotho in patients with ESKD.
The mechanisms responsible for the small transient reduction in soluble Klotho levels during cinacalcet treatment are unknown; however, the absence of associations between changes in soluble Klotho and changes in other parameters of SHPT suggests that cinacalcet has a direct effect on circulating soluble Klotho. Whether CaSR regulates secretion of soluble Klotho from the kidney or parathyroid should be examined in future studies.
Recently, Klotho has been shown to directly inhibit phosphate uptake by vascular smooth muscles in vitro [17] . This study, however, found that cinacalcet did not increase serum soluble Klotho, despite its beneficial effect of attenuating vascular calcification [18] . Further 
